StocksMedium•12 November 2026•
1 min read
FDA Mandates Eye Risk Warnings for Ozempic and Zepbound
Key Facts
1The US FDA has ordered the addition of eye risk warnings to the labels of Ozempic and Zepbound medications.
The US FDA has ordered the addition of eye risk warnings to the labels of Ozempic and Zepbound medications. Big News Network reported that the mandate affects these popular GLP-1 receptor agonists used in the treatment of obesity and diabetes.
The regulatory action follows reports or studies linking these medications to specific ocular conditions, prompting increased oversight for manufacturers Novo Nordisk and Eli Lilly. While these blockbuster drugs maintain high market demand, the new safety warnings represent a shift in the regulatory landscape for the GLP-1 class.